Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1986 4
1987 2
1991 1
1998 2
1999 1
2002 2
2003 2
2004 1
2005 2
2006 3
2007 3
2008 1
2009 5
2010 4
2011 5
2012 6
2013 8
2014 6
2015 6
2016 8
2017 6
2019 1
2020 4
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Biosimilars in the Treatment of Breast Cancer.
Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E. Balic M, et al. Among authors: vrbanec d. Breast Care (Basel). 2017 Jul;12(3):192-194. doi: 10.1159/000477926. Epub 2017 Jun 13. Breast Care (Basel). 2017. PMID: 28785188 Free PMC article. No abstract available.
Interleukin 17 in early invasive breast cancer.
Popović M, Dedić Plavetić N, Vrbanec D, Marušić Z, Mijatović D, Kulić A. Popović M, et al. Among authors: vrbanec d. Front Oncol. 2023 Jun 23;13:1171254. doi: 10.3389/fonc.2023.1171254. eCollection 2023. Front Oncol. 2023. PMID: 37427128 Free PMC article.
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan AA, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B; Central European Cooperative Oncology Group (CECOG); Swiss Group for Clinical Cancer Research (SAKK). Rordorf T, et al. Among authors: vrbanec d. Breast. 2014 Oct;23(5):511-25. doi: 10.1016/j.breast.2014.05.023. Epub 2014 Jun 27. Breast. 2014. PMID: 24986766 Free article.
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.
Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussen H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. Belkacemi Y, et al. Among authors: vrbanec d. Eur J Cancer. 2020 Aug;135:130-146. doi: 10.1016/j.ejca.2020.05.015. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32580130 Free PMC article. Review.
Gastric cancer detection using the serum pepsinogen test method.
Trivanovic D, Plestina S, Honovic L, Dobrila-Dintinjana R, Vlasic Tanaskovic J, Vrbanec D. Trivanovic D, et al. Among authors: vrbanec d. Tumori. 2022 Aug;108(4):386-391. doi: 10.1177/03008916211014961. Epub 2021 May 17. Tumori. 2022. PMID: 33993805
80 results